Clinical Focus ›› 2023, Vol. 38 ›› Issue (10): 944-948.doi: 10.3969/j.issn.1004-583X.2023.10.016
Previous Articles Next Articles
-
Received:2023-03-22Online:2023-10-20Published:2024-01-03
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.10.016
| [1] |
Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry[J]. Chest, 2010, 137: 376-387.
doi: 10.1378/chest.09-1140 pmid: 19837821 |
| [2] | 钱君岩, 赵久良, 王迁, 等. 《中国肺动脉高压诊断与治疗指南(2021版)》解读——结缔组织病相关肺动脉高压[J]. 中国实用内科杂志, 2021, 41(12):1030-1034. |
| [3] |
Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: Identifying systemic sclerosis as a unique phenotype[J]. Chest, 2010, 138: 1383-1394.
doi: 10.1378/chest.10-0260 pmid: 20507945 |
| [4] |
Hao YJ, Jiang X, Zhou W, et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients[J]. Eur Respir J, 2014, 44: 963-972.
doi: 10.1183/09031936.00182813 URL |
| [5] | 张晓, 赵久良, 丁峰, 等. 结缔组织病相关肺动脉高压诊疗规范[J]. 中华内科杂志, 2022, 61(11) : 1206-1216. |
| [6] | 樊丽娟, 李闪闪, 王衍, 等. 结缔组织病相关肺动脉高压的临床特点及生存分析[J]. 郑州大学学报:医学版, 2022, 57(5):609-615. |
| [7] |
Zhao J, Wang Q, Liu Y, et al. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China[J]. Int J Cardiol, 2017, 236: 432-437.
doi: S0167-5273(16)34499-0 pmid: 28159359 |
| [8] | 潘婕. 三种结缔组织病相关肺动脉高压的临床特点及预后分析[D]. 南宁: 广西医科大学, 2019. |
| [9] |
van Uden D, Boomars K, Kool M. Dendritic cell subsets and effector function in idiopathic and connective tissue disease-associated pulmonary arterial hypertension[J]. Front Immunol, 2019, 10: 11.
doi: 10.3389/fimmu.2019.00011 pmid: 30723471 |
| [10] |
Pullamsetti SS, Seeger W, Savai R. Classical IL-6 signaling: A promising therapeutic target for pulmonary arterial hypertension[J]. J Clin Invest, 2018, 128: 1720-1723.
doi: 10.1172/JCI120415 pmid: 29629898 |
| [11] |
Wang L, Liu J, Wang W, et al. Targeting IL-17 attenuates hypoxia-induced pulmonary hypertension through downregulation of β-catenin[J]. Thorax, 2019, 74: 564-578.
doi: 10.1136/thoraxjnl-2018-211846 pmid: 30777899 |
| [12] | 张森, 陈延军. 肺动脉高压中炎性反应与免疫反应的发生机制[J]. 医学研究杂志, 2017, 46(4):14-16, 51. |
| [13] |
Li C, Liu PP, Tang DD, et al. Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension[J]. Pulm Pharmacol Ther, 2018, 50: 111-122.
doi: S1094-5539(17)30285-7 pmid: 29673911 |
| [14] | 朱珊英. 免疫功能失调及细胞因子异常与结缔组织相关肺动脉高压的相关性研究[D]. 太原: 山西医科大学, 2020. |
| [15] |
Nicolls MR, Voelkel NF. The Roles of immunity in the prevention and evolution of pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2017, 195: 1292-1299.
doi: 10.1164/rccm.201608-1630PP URL |
| [16] | 李青, 李宏义. 血管外膜成纤维细胞在肺动脉高压中的作用及研究进展[J]. 医学研究杂志, 2020, 49(11):25-28, 32. |
| [17] | 荆志成. 国人肺动脉高压遗传特征及发病机制的探索与应用[D]. 北京: 北京协和医院, 2020. |
| [18] |
Fan Y, Hao YJ, Gao D, et al. Phenotype and function of macrophage polarization in monocrotaline-induced pulmonary arterial hypertension rat model[J]. Physiol Res, 2021, 70: 213-226.
doi: 10.33549/physiolres.934456 pmid: 33676385 |
| [19] |
Tang C, Luo YM, Li S, et al. Characteristics of inflammation process in monocrotaline-induced pulmonary arterial hypertension in rats[J]. Biomed Pharmacother, 2021, 133: 111081.
doi: 10.1016/j.biopha.2020.111081 pmid: 33378977 |
| [20] | 郭迪森, 张榕. 结缔组织病相关肺动脉高压免疫代谢机制的研究进展[J]. 中华风湿病学杂志, 2022, 26(3):205-209. |
| [21] | 孙焕霞, 苏厚恒, 石颜军. 系统性硬化病发病机制探讨及展望[J]. 中华风湿病学杂志, 2020, 24 (7): 491-495. |
| [22] | 李然. 结缔组织病相关肺动脉高压的危险因素及预后分析[D]. 大连: 大连医科大学, 2021. |
| [23] | 汪汉, 何春容. 系统性红斑狼疮相关肺动脉高压的流行病学及发病机制[J]. 心血管病学进展, 2019, 40(4):544-546. |
| [24] |
Minopoulou I, Theodorakopoulou M, Boutou A, et al. Nailfold capillaroscopy in systemic sclerosis patients with and without pulmonary arterial hypertension: A systematic review and meta-analysis[J]. J Clin Med, 2021, 10(7):1528.
doi: 10.3390/jcm10071528 URL |
| [25] |
Donnarumma JFS, Ferreira EVM, Ota-Arakaki J, et al. Nailfold capillaroscopy as a risk factor for pulmonary arterial hypertension in systemic lupus erythematosus patients[J]. Adv Rheumatol, 2019, 59: 1.
doi: 10.1186/s42358-018-0045-5 pmid: 30657102 |
| [26] | 郝俊峰, 陈建建. 从肠道菌群论治肺系疾病[J]. 临床合理用药杂志, 2022, 15(28):177-181. |
| [27] | 于尧, 韩毓梅, 周金哲, 等. 肠道菌群失调与皮肤科常见结缔组织病相关性概述[J]. 中华皮肤科杂志, 2020, 53(4):308-311. |
| [28] |
Brunner K, Samassa F, Sansonetti PJ, et al. Shigella-mediated immunosuppression in the human gut: Subversion extends from innate to adaptive immune responses[J]. Hum Vaccin Immunother, 2019, 15: 1317-1325.
doi: 10.1080/21645515.2019.1594132 URL |
| [29] | 辛晓红, 茹美华, 张升校, 等. 结缔组织病相关肺动脉高压患者肠道菌群分布变化与外周血T淋巴细胞亚群和细胞因子的相关性分析[J]. 中国分子心脏病学杂志, 2021, 21(3):4010-4016. |
| [30] | Zou HX, Qiu BQ, Lai SQ, et al. Iron metabolism and idiopathic pulmonary arterial hypertension: New insights from bioinformatic analysis[J]. Biomed Res Int, 2021, 2021: 1-27. |
| [31] | 禹雪. 肺动脉高压患者氧代谢相关临床研究[D]. 北京: 北京协和医学院, 2019. |
| [32] |
Goyal KK, Saha A, Sahi PK, et al. Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study[J]. Clin Nephrol, 2018, 89: 363-370.
doi: 10.5414/CN109132 URL |
| [33] |
Ramakrishnan L, Pedersen SL, Toe QK, et al. Pulmonary arterial hypertension: Iron matters[J]. Front Physiol, 2018, 9: 641.
doi: 10.3389/fphys.2018.00641 pmid: 29904352 |
| [34] | 师悦, 李慕聪, 赵久良, 等. 结缔组织病相关肺动脉高压的遗传学[J]. 中华临床免疫和变态反应杂志, 2020, 14(6):581-586. |
| [35] |
Takagi K, Kawamoto M, Higuchi T, et al. Single nucleotide polymorphisms of the HIF1A gene are associated with susceptibility to pulmonary arterial hypertension in systemic sclerosis and contribute to SSc-PAH disease severity[J]. Int J Rheum Dis, 2020, 23: 674-680.
doi: 10.1111/1756-185X.13822 pmid: 32144871 |
| [36] | Huang C, Yang J, Li MT, et al. CBLN2 rs2217560 was associated with pulmonary arterial hypertension in systemic lupus erythematosus[J]. Chin Med J:Engl, 2018, 131: 3020-3021. |
| [37] | 王婕颖. 原发性干燥综合征相关肺动脉高压的临床队列及生物标志物研究[D]. 北京: 北京协和医学院, 2017. |
| [38] |
Liu Z, Yang X, Tian Z, et al. The prognosis of pulmonary arterial hypertension associated with primary sjögren's syndrome: a cohort study[J]. Lupus, 2018, 27: 1072-1080.
doi: 10.1177/0961203318756287 pmid: 29419347 |
| [39] |
Hu S, Hou Y, Wang Q, et al. Prognostic profile of systemic sclerosis: Analysis of the clinical EUSTAR cohort in China[J]. Arthritis Res Ther, 2018, 20: 235.
doi: 10.1186/s13075-018-1735-4 pmid: 30348207 |
| [40] | 王媛媛, 孙晓萱, 黄颖恒, 等. 血清可溶性生长刺激表达基因2蛋白在结缔组织病相关肺动脉高压中的应用价值[J]. 临床内科杂志, 2020, 37(5):365-367. |
| [41] | 金艳盛, 朱赟, 李伟, 等. 血清25羟基维生素D水平在结缔组织病相关肺动脉高压患者中的临床意义[J]. 中华风湿病学杂志, 2022, 26(2):91-98. |
| [42] | 周持恒, 王钦清. 探讨结缔组织病相关肺动脉高压的临床特点以及临床意义[J]. 实用心脑肺血管病杂志, 2020, 28(S1):101-102. |
| [43] | 苗风楠, 史晓飞, 马新. 结缔组织病继发肺动脉高压的影响因素分析[J]. 河南医学高等专科学校学报, 2021, 33(6):676-680. |
| [44] | 刘娟. 非对称二甲基精氨酸检测对结缔组织病相关肺动脉高压的临床价值[D]. 南昌: 南昌大学, 2019. |
| [45] | 李智腾, 范观止, 段培青, 等. 原发性干燥综合征患者合并肺动脉高压危险因素分析[J]. 中国医科大学学报, 2018, 47(5):420-425. |
| [46] |
Wang J, Li M, Wang Q, et al. Pulmonary arterial hypertension associated with primary sjögren's syndrome: A multicentre cohort study from China[J]. Eur Respir J. 2020, 56(5):1902157.
doi: 10.1183/13993003.02157-2019 URL |
| [47] | 崔祥祥, 杨骥, 屠文震, 等. 130例系统性硬化病患者肺动脉高压的检测及其高危因素分析[J]. 临床皮肤科杂志, 2022, 51(4):204-207. |
| [48] | 朱玲娴, 赵荫环, 张蕊, 等. 系统性硬化症发生肺动脉高压的独立危险因素分析[J]. 风湿病与关节炎, 2023, 12(1):14-18. |
| [49] | 金方圆. 系统性红斑狼疮相关肺动脉高压的临床回顾性分析[D]. 合肥: 安徽医科大学, 2019. |
| [50] |
Wang J, Qian J, Wang Y, et al. Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: A systematic review and meta-analysis[J]. Lupus, 2017, 26: 1390-1400.
doi: 10.1177/0961203317702255 pmid: 28409522 |
| [51] |
Hachulla E, Jais X, Cinquetti G, et al. Pulmonary arterial hypertension associated with systemic lupus erythematosus: Results from the french pulmonary hypertension registry[J]. Chest, 2018, 153: 143-151.
doi: S0012-3692(17)31430-7 pmid: 28851621 |
| [52] | 宋俊梅. 平板运动负荷超声心动图评价结缔组织病右心室收缩功能及其储备[D]. 泸州: 西南医科大学, 2021. |
| [53] | 马红, 周蕾, 王嫱, 等. 二维斑点追踪显像技术评估结缔组织病合并肺动脉高压患者右心室收缩功能的临床研究[J]. 中国循环杂志, 2020, 35(9):910-915. |
| [54] | 宁红霞. 三维超声心动图斑点追踪技术评价结缔组织病相关肺动脉高压患者的心室功能[D]. 沈阳: 中国医科大学, 2018. |
| [55] | 郑丽远, 李扬, 陈巘, 等. 双源CT在诊断结缔组织病肺间质病变致肺动脉高压中的应用[J]. 罕少疾病杂志, 2017, 24(4):3-4, 7. |
| [56] |
Zhang N, Li M, Qian J, et al. Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors[J]. Int J Rheum Dis, 2019, 22(5): 921-928.
doi: 10.1111/1756-185X.13478 pmid: 30746850 |
| [57] |
Huang C, Li M, Liu Y, et al. Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients[J]. Medicine, 2016, 95(10): e2761.
doi: 10.1097/MD.0000000000002761 URL |
| [58] | Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Rev Esp Cardiol(Engl Ed), 2016, 69(2): 177. |
| [59] |
Young A, Nagaraja V, Basilious M, et al. Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension[J]. Semin Arthritis Rheum, 2019, 48(6): 1059-1067.
doi: 10.1016/j.semarthrit.2018.10.010 URL |
| [60] |
Yan S, Li M, Wang H, et al. Characteristics and risk factors of pulmonary arterial hypertension in patients with primary Sjogren's syndrome[J]. Int J Rheum Dis, 2018, 21(5): 1068-1075.
doi: 10.1111/apl.2018.21.issue-5 URL |
| [1] | Song Jialiang, Jiang Yingjie, Kong Ruina, Cai Qing, Gao Jie. IgG4-related diseases characterized by increased IgE level and eosinophil count with multiple lymphadenopathy: A case report [J]. Clinical Focus, 2024, 39(1): 57-60. |
| [2] | . [J]. Clinical Focus, 2024, 39(1): 92-96. |
| [3] | He Peihua, Zhou Xingfu, Hong Weihong, Wang Lichun, Liu Sujun, Jin Yuyan, Zeng Jiahao, Liu Lichang. Clinical analysis of 4 cases of IgG4-related kidney disease [J]. Clinical Focus, 2023, 38(11): 1016-1021. |
| [4] | . [J]. Clinical Focus, 2023, 38(8): 753-756. |
| [5] | . [J]. Clinical Focus, 2023, 38(7): 663-667. |
| [6] | . [J]. Clinical Focus, 2023, 38(3): 279-284. |
| [7] | Gao Ying, Han Zhongli, Wang Hongyan, Li Xiaofu. Magnetic resonance imaging characteristics of Andersson lesions associated with ankylosing spondylitis [J]. Clinical Focus, 2022, 37(10): 927-930. |
| [8] | Zhang Yueyue, Xie Meifang, Sun Gen. Rheumatoid arthritis complicated with T-cell large granular lymphocytic leukemia: A case report and literature review [J]. Clinical Focus, 2022, 37(8): 728-732. |
| [9] | Lin Changyi, Song Minghui, Wu Peicheng. Effects of diagnosis age on clinical manifestations of polymyalgia rheumatica: A single center retrospective cohort study on 68 patients [J]. Clinical Focus, 2022, 37(7): 612-615. |
| [10] | Qin Meijie, Tian Maolu, Yang Yuqi, Zha Yan, Yuan Jing. Literature review on treatment of immune thrombocytopenia secondary to refractory systemic lupus erythematosus with belimumab combined with cyclosporine: A case report and literature review [J]. Clinical Focus, 2022, 37(6): 544-547. |
| [11] | . [J]. Clinical Focus, 2022, 37(5): 472-476. |
| [12] | Hu Fangfang, Zhong Shiling, Di Yazhen, Wu Ling. Vascular endothelial function of juvenile idiopathic arthritis in pediatric patients: A systematic review and meta-analysis [J]. Clinical Focus, 2022, 37(3): 204-210. |
| [13] | Lin Changyi, Song Minghui, Wu Peicheng. Difference between remitting seronegative symmetrical synovitis with pitting edema syndrome and seronegative rheumatoid arthritis [J]. Clinical Focus, 2022, 37(3): 262-265. |
| [14] | . [J]. Clinical Focus, 2022, 37(2): 188-192. |
| [15] | . [J]. Clinical Focus, 2022, 37(1): 92-96. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||